AEHR TEST SYSTEMS WKN: 908802 ISIN: US00760J1088 Forum: Aktien Thema: Hauptdiskussion

Aehr Test Systems Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results and Provides Fiscal 2025 Full Year Financial Guidance 07/16/2024 FREMONT, CA / ACCESSWIRE / July 16, 2024 / Aehr Test Systems (NASDAQ:AEHR), a worldwide supplier of semiconductor test and burn-in equipment, today announced financial results for its fiscal 2024 fourth quarter and full year ended May 31, 2024. Fiscal Fourth Quarter Financial Results: Net revenue was $16.6 million, compared to $22.3 million in the fourth quarter of fiscal 2023 GAAP net income was $23.9 million, or $0.81 per diluted share, which includes the impact of a tax benefit resulting from the release of the Company's full income tax valuation allowance of approximately $20.8 million, compared to GAAP net income of $6.1 million, or $0.21 per diluted share, in the fourth quarter of fiscal 2023. Non-GAAP net income was $24.7 million, or $0.84 per diluted share, which includes the tax benefit and excludes acquisition related costs and the impact of stock-based compensation, compared to non-GAAP net income of $6.8 million, or $0.23 per diluted share, in the fourth quarter of fiscal 2023. Bookings were $4.0 million for the quarter Backlog as of May 31, 2024, was $7.3 million. Effective backlog, which includes all orders received since the end of the fourth quarter, is $20.8 million. Total cash and cash equivalents as of May 31, 2024 were $49.2 million, up from $47.6 million at February 29, 2024 Fiscal Year Financial Results: Net revenue was a record $66.2 million, compared to $65.0 million in fiscal 2023 GAAP net income was $33.2 million, or $1.12 per diluted share, which includes the impact of a tax benefit resulting from the release of the Company's full income tax valuation allowance of approximately $20.8 million recognized in the fourth quarter, compared to GAAP net income of $14.6 million, or $0.50 per diluted share, in fiscal 2023. Non-GAAP net income, which includes the tax benefit and excludes acquisition related costs and the impact of stock-based compensation, was $35.8 million, or $1.21 per diluted share, compared to non-GAAP net income of $17.3 million, or $0.59 per diluted share, in fiscal 2023. An explanation of the use of non-GAAP financial measures and a reconciliation of Aehr's non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying tables.

3 Jahre halten und mit lächerlichen 200 stück in Rente gehen^^?

könnte vielleicht eine NVIDIA werden 😍

Hast du die Earnings? Ich finde nix, Techii sagt irgendwas von 730% overperformance?

nope

dein persönliches Kursziel? 😜

ich verkaufe nicht.......ich will mehr - viel mehr :-)

bietet ING nicht L&S an ?

AEHR TEST SYSTEMS werden morgen fliegen .......😍😍😍

Über die ING geht nach 22:00 nixmehr, ich bleib sowieso mal drin und schau mir den spaß morgen an

man kann doch über L&S noch handeln

Mein Broker hat die Schotten dicht, ich kann sowieso nur zusehen 😜 Vielleicht ist das auch besser so

ach was......

Ich wünsche euch weiterhin viel Glück, ich bin jetzt raus 😳🙋‍♂️.

gleich kommt noch eine Videostream https://www.webcaster4.com/Player/Index?webcastId=50772&g=2ad040b3-3ece-429b-8bfc-c8d4b08319f4&uid=7028238&sid=

18€ bei l und s